San Francisco Sentry Investment Group Ca Boosted Its 3M Co (MMM) Holding; Last Week Oxford BioMedica PLC (LON:OXB) Coverage

January 22, 2018 - By Henry Gaston

Among 4 analysts covering Oxford BioMedica PLC (LON:OXB), 2 have Buy rating, 1 Sell and 1 Hold. Therefore 50% are positive. Oxford BioMedica PLC had 20 analyst reports since August 27, 2015 according to SRatingsIntel. The stock of Oxford BioMedica PLC (LON:OXB) earned “Hold” rating by N+1 Singer on Tuesday, November 29. Peel Hunt maintained it with “Buy” rating and GBX 13 target in Monday, January 8 report. The firm has “Sell” rating by N+1 Singer given on Monday, March 7. The rating was maintained by N+1 Singer on Thursday, July 6 with “Hold”. The stock has “Buy” rating by N+1 Singer on Friday, January 29. The firm has “Buy” rating by Jefferies given on Thursday, July 13. The firm has “Buy” rating given on Thursday, January 5 by Jefferies. N+1 Singer maintained the stock with “Buy” rating in Wednesday, November 4 report. The company was maintained on Thursday, August 31 by Jefferies. N+1 Singer upgraded the stock to “Hold” rating in Friday, October 14 report. See Oxford BioMedica PLC (LON:OXB) latest ratings:

08/01/2018 Broker: Peel Hunt Rating: Buy Old Target: GBX 13.00 New Target: GBX 13.00 Maintain
31/10/2017 Broker: Peel Hunt Rating: Buy Old Target: GBX 13.00 New Target: GBX 13.00 Maintain
19/09/2017 Broker: Peel Hunt Rating: Buy New Target: GBX 13.00 Initiates Starts
31/08/2017 Broker: N+1 Singer Rating: Hold Old Target: GBX 8.70 New Target: GBX 10.20 Maintain
31/08/2017 Broker: Jefferies Rating: Buy Old Target: GBX 13.00 New Target: GBX 13.00 Maintain

San Francisco Sentry Investment Group Ca increased 3M Co (MMM) stake by 26.34% reported in 2017Q3 SEC filing. San Francisco Sentry Investment Group Ca acquired 2,094 shares as 3M Co (MMM)’s stock rose 7.02%. The San Francisco Sentry Investment Group Ca holds 10,045 shares with $2.11M value, up from 7,951 last quarter. 3M Co now has $147.27B valuation. The stock decreased 0.37% or $0.92 during the last trading session, reaching $247.26. About 916,049 shares traded. 3M Company (NYSE:MMM) has risen 18.59% since January 22, 2017 and is uptrending. It has outperformed by 1.89% the S&P500.

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company has market cap of 344.51 million GBP. The firm operates through Partnering and R&D divisions. It currently has negative earnings. The Company’s LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

The stock increased 6.73% or GBX 0.7 during the last trading session, reaching GBX 11.1. About 12.91 million shares traded or 121.36% up from the average. Oxford BioMedica PLC (LON:OXB) has 0.00% since January 22, 2017 and is . It has underperformed by 16.70% the S&P500.

Among 15 analysts covering 3M (NYSE:MMM), 7 have Buy rating, 3 Sell and 5 Hold. Therefore 47% are positive. 3M had 72 analyst reports since July 24, 2015 according to SRatingsIntel. As per Monday, July 10, the company rating was maintained by RBC Capital Markets. The firm has “Buy” rating by UBS given on Wednesday, December 16. The firm has “Buy” rating by Jefferies given on Friday, May 26. Jefferies maintained the stock with “Buy” rating in Monday, May 29 report. The firm has “Underweight” rating given on Monday, October 2 by Morgan Stanley. As per Wednesday, December 16, the company rating was maintained by RBC Capital Markets. Morgan Stanley maintained the shares of MMM in report on Wednesday, March 30 with “Underweight” rating. Stifel Nicolaus maintained the stock with “Hold” rating in Wednesday, January 25 report. Credit Suisse maintained 3M Company (NYSE:MMM) on Friday, April 28 with “Buy” rating. On Thursday, January 21 the stock rating was initiated by Citigroup with “Buy”.

Echostar Corporation-Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>